3-[(3-Trifluoromethyl)phenyl]-1-propene

1-Allyl-3-(trifluoromethyl)benzene is an impurity of Cinacalcet (C441790), which is the first calcimimetic drug approved by the United States Food and Drug Administration for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.